Aptose Biosciences Financials
| APS Stock | CAD 5.10 0.56 9.89% |
Aptose |
Understanding current and past Aptose Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Aptose Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Aptose Biosciences' assets may result in an increase in income on the income statement.
Aptose Biosciences Stock Summary
Aptose Biosciences competes with Medicenna Therapeutics, and Oncolytics Biotech. Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada. APTOSE BIOSCIENCES operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 22 people.| Foreign Associate | USA |
| Instrument | Canada Stock View All |
| Exchange | Toronto Exchange |
| ISIN | CA03835T2002 |
| Business Address | 251 Consumers Road, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.aptose.com |
| Phone | 647 479 9828 |
| Currency | CAD - Canadian Dollar |
You should never invest in Aptose Biosciences without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Aptose Stock, because this is throwing your money away. Analyzing the key information contained in Aptose Biosciences' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Aptose Biosciences Key Financial Ratios
Aptose Biosciences' financial ratios allow both analysts and investors to convert raw data from Aptose Biosciences' financial statements into concise, actionable information that can be used to evaluate the performance of Aptose Biosciences over time and compare it to other companies across industries.| Return On Equity | -6.94 | |||
| Return On Asset | -1.42 | |||
| Target Price | 31.02 | |||
| Number Of Employees | 35 | |||
| Beta | 1.13 |
Aptose Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aptose Biosciences's current stock value. Our valuation model uses many indicators to compare Aptose Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aptose Biosciences competition to find correlations between indicators driving Aptose Biosciences's intrinsic value. More Info.Aptose Biosciences is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Aptose Biosciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Aptose Biosciences' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Aptose Biosciences Systematic Risk
Aptose Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Aptose Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Aptose Biosciences correlated with the market. If Beta is less than 0 Aptose Biosciences generally moves in the opposite direction as compared to the market. If Aptose Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Aptose Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Aptose Biosciences is generally in the same direction as the market. If Beta > 1 Aptose Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Aptose Biosciences March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Aptose Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Aptose Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Aptose Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Aptose Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aptose Biosciences's daily price indicators and compare them against related drivers.
| Downside Deviation | 8.9 | |||
| Information Ratio | 0.1199 | |||
| Maximum Drawdown | 1009.89 | |||
| Value At Risk | (12.50) | |||
| Potential Upside | 9.07 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.